Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry

Circulation

Volumn 128, Issue 7, 2013, Pages 721-728

  Steinberg, Benjamin A ^a,b   Kim, Sunghee ^b   Piccini, Jonathan P ^a,b   Fonarow, Gregg C ^c   Lopes, Renato D ^a,b   Thomas, Laine ^b   Ezekowitz, Michael D ^b,d   Ansell, Jack ^e   Kowey, Peter ^d   Singer, Daniel E ^f   Gersh, Bernard ^g   Mahaffey, Kenneth W ^a   Hylek, Elaine ^h   Go, Alan S ⁱ   Chang, Paul ^j   Peterson, Eric D ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MAYO CLINIC   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Anticoagulants; Aspirin; Atrial fibrillation; Hemorrhage; Outcome assessment (health care)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DABIGATRAN;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION AND RISK FACTORS IN ATRIAL FIBRILLATION SCORE; ARTICLE; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG FATALITY; DRUG SAFETY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; HEMORRHAGE; OUTCOME ASSESSMENT (HEALTH CARE);

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CEREBROVASCULAR DISORDERS; COMORBIDITY; DRUG SYNERGISM; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITALIZATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; RISK; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84882242349     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002927     Document Type: Article

References (27)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation. 2004;110:1042-1046.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991;22:983-988.
3. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, White HD, Wallentin L, Granger CB. Short-and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94:867-873.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e269-e367.
6. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation: Rationale and design of ORBIT-AF. Am Heart J. 2011;162:606-612.e1.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
8. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.
9. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395-401.
10. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
11. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405-410.
12. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
13. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-2294.
14. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
15. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433-1441.
16. Johnson SG, Witt DM, Eddy TR, Delate T. Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest. 2007;131:1500-1507.
17. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-analysis of randomized trials. Arch Intern Med. 2007;167:117-124.
18. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967-973.
19. Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest. 2008;133:948-954.
20. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Gardin JM, O'Rourke RA, Williams SV, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force On Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Circulation. 2007;116:2762-2772.
21. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
22. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
23. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
24. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE; Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet. 2002;360:109-113.
25. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519-526.
26. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.
27. Douketis JD. Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why? Thromb Res. 2011;127:513-517.